Keensight Capital has reached an agreement to invest alongside management in Axxam.
Axxam has obtained a license from iPS Academia Japan to use iPS cells and iPS-derived cells for drug discovery services
With the aim to offer drug discovery services using human induced pluripotent stem cells (iPS cells) and iPS-derived cells, Axxam has entered into a license agreement with iPS Academia Japan.
The two German subsidiaries of Axxam S.p.A., Hit Discovery Constance GmbH and IMAX Discovery GmbH, merged into Axxam GmbH
Axxam announces the launch of Muna Therapeutics ApS with EUR 60 Million to advance novel small molecule therapeutics for neurodegenerative diseases
Axxam is proud to announce that Muna Therapeutics, a biotech company founded in 2020 by Aarhus University, financed by Novo Seeds and receiving assets in exchange of equity from Axxam, was successful closing a EUR 60 million (US$ 73 million) Series A financing round today.
Axxam announces its participation in the REsolution consortium, a public-private research partnership supported by the Innovative Medicines Initiative (IMI), to accelerate research in the field of solute carrier (SLC) class of transporters.
Axxam is proud to announce the entire acquisition of the share capital of Hit Discovery Constance GmbH (“HDC”). As a consequence, HDC founded in 2014 as a joint venture between Axxam, Centre for Drug Design and Discovery of KU Leuven and Lead Discovery Center GmbH, is now a subsidiary of Axxam.
Thanks to the long-standing collaboration with Symeres (recently rebranded from MercachemSyncom), Axxam has access to an additional library of approx. 80,000 lead-like compounds synthetized at Symeres, named Symegold library, for use in high-throughput screens.
Axxam, leadXpro and MercachemSyncom Form a Strategic Alliance for Structure-based Drug Discovery Services
Bresso (Italy), Villigen (Switzerland) and Nijmegen (the Netherlands) – Axxam, leadXpro and MercachemSyncom today announced a strategic alliance that will allow them to offer world-class integrated structure-guided drug discovery services for membrane protein targets.
Axxam and FUJIFILM Cellular Dynamics announce strategic alliance to deliver integrated hiPSC drug discovery solutions
Axxam and FUJIFILM Cellular Dynamics announce strategic alliance to deliver integrated hiPSC drug discovery solutions Oct 8, 2020 MILAN (Italy) and MADISON (Wis., USA) - Axxam S.p.A., a leading provider of integrated drug discovery services across life sciences...
Axxam announces the launch of Libra Therapeutics to develop novel therapies targeting neurodegenerative diseases
Axxam announces the launch of Libra Therapeutics to develop novel therapies targeting neurodegenerative diseases Sept 24, 2020 Milan (Italy) – Axxam is proud to announce that Libra Therapeutics, a privately held US biotech company founded in mid-2019 by Axxam and...
Selonterra and Axxam Enter into Drug Discovery Collaboration June 16, 2020 San Mateo, California (USA) and Milan, Italy - Selonterra, Inc., a biotechnology company developing transformative therapies for neurodegenerative disorders, and Axxam S.p.A., a leading...
Axxam enters into Drug Discovery Collaboration with Vivozon for CNS Indications May 12, 2020 Axxam announces a collaboration with Vivozon Inc. with the aim to support Vivozon in the development of innovative small molecule drugs for the treatment of patients with...